Complete and acceptable symptom remission in rheumatoid arthritis: PASS-based thresholds derived from the Okomarigoto Sheet

Clicks: 18
ID: 328151
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #172 of 339 articles by views in Lara D. Veeken

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 339 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
OBJECTIVES: Residual symptoms frequently persist despite clinical remission in rheumatoid arthritis (RA). Although complete absence of residual symptoms is associated with favorable outcomes, an acceptable level of residual symptoms has not been defined. This study aimed to establish clinically meaningful thresholds for residual symptoms assessed by the Okomarigoto Sheet (OS) and evaluate their clinical validity using the Patient Acceptable Symptom State (PASS). METHODS: This cross-sectional study included 370 patients with RA, including 213 who achieved Simplified Disease Activity Index (SDAI) remission. Residual symptoms were assessed using the OS, and PASS was used as an external anchor. OS thresholds were determined using the 75th percentile method and evaluated by ROC analysis. Clinical validity was assessed by the proportion of patients reporting PASS, Health Assessment Questionnaire-Disability Index (HAQ-DI), and patient global assessment (PGA). RESULTS: Among 370 patients, 284 reported PASS. The 75th percentile method identified OS thresholds of 3 in the overall cohort and 2 among patients achieving SDAI remission. ROC analysis demonstrated good discrimination for patients reporting PASS (AUC 0.824 and 0.838, respectively). The proportion of patients reporting PASS decreased across increasing OS categories in both the overall cohort (95.2%, 83.9%, and 46.8%; p < 0.0001) and the SDAI remission subgroup (99.0%, 95.7%, and 71.4%; p < 0.0001). Lower OS scores were also associated with better physical function and lower PGA scores. CONCLUSIONS: OS-defined symptom remission provides a clinically meaningful framework for evaluating acceptable residual symptom burden in RA. Assessment with the OS may complement conventional remission criteria and support more patient-centered treatment strategies.
Reference Key
openalex_W7212033605 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Kensuke Koyama, Tetsuro Ohba, Ryousuke Koizumi, Koki Watabe, Hirotaka Haro
Are you one of these authors? Claim your profile
Journal Lara D. Veeken
Year 2026
DOI
10.1093/rheumatology/keag491
URL
https://doi.org/10.1093/rheumatology/keag491
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.